The sample consisted of 48 female participants, over 50 years of age and divided into two groups. The participants were submitted to botulinum toxin application in the upper third of the face, specifically in the frontal muscle, and in 24 participants the dilution of Botulinum Toxin was with 0.02% Zinc Gluconate Solution (Case Group) and 24 participants with dilution Of Botulinum Toxin in 0.9% Physiological Solution (Control Group). Not Applicable
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. All female participants 2. 50 years of age or older 3. Agreed to the study and signed the informed consent form 4. No history of chronic gastrointestinal disease (diarrhea, inflammatory bowel disease or celiac disease) with frontal wrinkles 5. Muscle contraction (dynamic) 6. At least 6 months without receiving botulinum toxin application for any indication 7. Participants who were never submitted to this treatment
Exclusion criteria
Exclusion criteria: 1. Individuals of the male gender 2. Female subjects under 50 years of age 3. Did not agree to the study and did not sign the informed consent form 4. History of chronic gastrointestinal disease (diarrhea, inflammatory bowel disease, or Celiac disease) 5. Diabetes mellitus 6. Lack of wrinkles to muscle contraction (dynamic or static) 7. Underwent botulinum toxin treatment for less than 6 months for any indication were not included in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Wrinkle evaluation (on movement and at rest) is measured using the Merz Aesthetics scale at baseline, weeks two, four and 14 2. Quality of life is measured using the WHO Quality of Life score at baseline and week 14 | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures. | — |
Countries
Brazil